COVID SUPPLY CHAINS: FACT NOT FICTION—CHAPTER 2, PART 1

The truth, the whole truth, and nothing but the truth

How is it going?

Hopefully, you will have gained some value from what has been shared so far from THE COVID-19 SUPPLY CHAIN: Fact not Fiction.

This next chapter is a wee bit longer, so I’ve split it into two parts. You may find, even this early, the critical thinker in you is asking important questions on what actually happened in developing the SARS-CoV-2 injetions, and what was required under Pharmaceutical Law. See what you think after reading Part 1 below:

CHAPTER 2 INDUSTRY AND REGULATION

There are two types of drugs produced in the industry:

Small molecule Product - that means they are made using industrial chemistry. Aspirin is an example. The pharmaceutical industry was mainly founded on small molecule products.

Biologic (large molecule) Product - biologics are essentially made from living things, such as animal and human cells. A monoclonal antibody is an example. There has been rapid growth of biologics in recent years.

There are two main business models involved:

Innovators (originators) – these are companies that carry out the R&D and market small-molecule and/or biologic products.

Generics/Biosimilars – these are companies that copy the original innovator products, either small molecule or biologic.

Regulatory Authorities